| Trial ID: | L5235 |
| Source ID: | NCT06240403
|
| Associated Drug: |
Digoxin 0.125 Mg
|
| Title: |
Digoxin and Senolysis in Heart Failure and Diabetes Mellitus
|
| Acronym: |
|
| Status: |
NOT_YET_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Heart Failure, Systolic|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Digoxin 0.125 MG
|
| Outcome Measures: |
Primary: SAT microvascular endothelial cell β-galactosidase, Change in MVEC senescence associated β-galactosidase expression in cultured MVEC will be assessed using CellEvent Senescence Green Detection Kit in fat biopsies., Three months |
|
| Sponsor/Collaborators: |
Sponsor: University of Leeds
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
100
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2025-09-01
|
| Completion Date: |
2029-08-28
|
| Results First Posted: |
|
| Last Update Posted: |
2024-12-06
|
| Locations: |
Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire, LS16 5AR, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT06240403
|
